Peptomyc, the spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and ICREA, and a member of CataloniaBio & HealthTech, has secured 8.6 million euros in funding from its current partners through a convertible loan. The next step is to open a round of funding of 25 million euros, with the aim of carrying out phase II of the clinical trial.

For the first 8.6 million, the biotechnology company has had the support of Alta Life Science, HealthEquity, Aurora Biosciences and various business angels, in addition to the CDTI, from the Spanish Ministry of Science and Innovation.

The company, led by Laura Soucek, will soon present the results of the phase I clinical trial for its OMO103 compound for the treatment of tumours and plans to start a phase II one soon. It is the company's first candidate in its project to develop a new generation of cell penetration peptides targeting the Myc oncoprotein, to be able to treat various types of cancer.

Peptomyc was founded in 2014 by Laura Soucek and Marie-Eve Beaulieu, scientific director. Since its founding, the company has raised more than 24 million euros.

Photo: Marie-Eve Beaulieu and Laura Soucek

You may  also be interested in:

• Peptomyc  starts Phase I/II clinical trial with cancer drug OMO-103
• Peptomyc  closes €11.4 million equity funding led by Aurora Science
• Peptomyc  gets €2.2 million through SME Instrument